Phase Ib Study of Ficlatuzumab With High Dose Cytarabine (HiDAC) in Relapsed and Refractory AML
Phase of Trial: Phase I
Latest Information Update: 13 Jun 2017
At a glance
- Drugs Ficlatuzumab (Primary) ; Cytarabine
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- 07 Jun 2017 Planned End Date changed from 1 Jan 2018 to 1 Jun 2019.
- 07 Jun 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2018.
- 06 Jun 2017 Results of dose-escalation phase (n=9) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology